Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-02-21
2006-02-21
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S247000, C544S232000, C544S240000
Reexamination Certificate
active
07001895
ABSTRACT:
The present invention describes pyridazinone compounds of formula Iwhich are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
REFERENCES:
patent: 3004027 (1961-10-01), Gordon et al.
patent: 4238490 (1980-12-01), Powers et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5580985 (1996-12-01), Lee et al.
patent: 5622948 (1997-04-01), Dunn et al.
patent: 5763440 (1998-06-01), Ross et al.
patent: 6307047 (2001-10-01), Black et al.
patent: 0711759 (1996-05-01), None
patent: 0714895 (1996-06-01), None
patent: 88/09675 (1988-12-01), None
patent: 95/00501 (1995-01-01), None
patent: 96/10012 (1996-04-01), None
patent: 96/16934 (1996-06-01), None
patent: 96/21662 (1996-07-01), None
patent: 96/24584 (1996-08-01), None
patent: 96/24585 (1996-08-01), None
patent: 96/25405 (1996-08-01), None
patent: 96/31509 (1996-10-01), None
patent: 96/36617 (1996-11-01), None
patent: 96/36623 (1996-11-01), None
patent: 96/37476 (1996-11-01), None
patent: 97/14691 (1997-04-01), None
patent: 98/41511 (1998-09-01), None
patent: 99/10331 (1999-03-01), None
patent: 99/10332 (1999-03-01), None
Vane, Nature, vol. 367, p. 215-216 (1994).
Griswold et al. Medicinal Research Reviews, vol. 16, p. 181-206 (1986).
Anzinger, H., et al., “Stabilizing Acid-labile Protecting Groups”, Angew. Chem., Int. Ed. Engl. 18(9) 686 (1979).
Eichholzer, J., et al., “Synthesis of (S)-N-(2,3-Dihydroxy-3-methylbutyl)acetamide”, Australian Journal of Chemistry 39(11) 1907-1909 (1986).
Browner, M., “X-ray crystal structure of human COX-2”,Roche Bioscience.
Battistini, B., et al., “COX-1 and COX-2: Toward the Development of More Selective NSAIDs”,DN&P, 7(8):501-512 (1994).
Bertenshaw, S.R., et al., Conformationally Restricted 1,5-Diarylpyrazoles are Selective COX-2 Inhibitors:,Bioorganic&Medicinal Chemistry Letters, 23:2827-2830 (1996).
Carruthers, N.I., et al., “Selective Cyclooxygenase Inhibitors”,Chemtracts-Organic Chemistry, 8:273-276 (1995).
Cashman, J.N., “The Mechanisms of Action of NSAIDs in Analgesia”,Drugs, 52(5):13-23 (1996).
Cho, S-D., “Concurrent Alkylation-Methoxylation of 4,5-Dihalopyridazin-6-ones and Synthesis of 5-Halo-4-hydroxypyridazin-6-ones”,J. Heterocyclic Chem., 33:1579-1582 (1996).
DeWitt, D.L., “The Differential Susceptibility of Prostaglandin Endoperoxide H Synthases 1 and -2 to Nonsteroidal Anti-inflammatory Drugs: Aspirin Derivatives as Selective Inhibitors”,Med. Chem. Res., 5:325-343 (1995).
Fieser & Fieser,Reagents for Organic Synthesis, 1: 172-173 (1967) John Wiley & Sons, NY, NY.
Ford-Hutchinson, A.W., “COX-2 inhibitors”,Merck Frosst Center for Therapeutic Research.
Freisen, R.W., “Novel 1,2-Diarylcyclobutenes: Selective and Orally Active Cox-2 Inhibitors”,Bioorganic&Medicinal Chemistry Letters, 6(22):2677-2682 (1996).
Frenette, R., et al., “Novel 1,2Diarylcyclobutenes: Selective and Orally Active COX-2 Inhibitors”,Merck Frosst Center for Therapeutic Research.
Gierse, et al, Expression and Selective Inhibition of the Constituitive and Inducible Forms of Cyclooxygenase,Biochem J., 305:479 (1995).
Gierse, J.K. et al, A Single Amino Acid Difference Between COX-1 and 2 Reverses the Selectivity of COX-2 Specific Inhibitors, Monsanto/Searle Research, p. 40.
Gauthier, J.Y., Synthesis and Biological Evaluation of 2,3-Diarylthiopenes as Selective COX-2 Inhibitors. Part II: Reolacing the Heterocycle, Bioorganic & Medicinal Chemistry Letters, 6(1):87-92 (1996).
Huang, H-C, Diaryl Indenes and Benzofurans: Novel Classes of Potent and Selective and Cyclooxygenase2 Inhibitors, Bioorganic & Medicinal Chemistry Letters, 5(20):2377-2380 (1995).
Schmid, G., et al., “Reaction of Areneselenyl Chlorides and Alkenes. An Example of neucleophilic Displacement at Bivalent Selenium”, J.Org. Chem, 48:4169-4172 (1983).
Krief, A., et al., “Synthesis of Selenones: A Comparative Study”, J. Org. Chem Soc., Chem. Comm.. 569570 (1985).
Hoffman, R., et al, “2-[[(p-Nitrophenyl)sulfonyl]oxy] 3-Keto Esters as Intermediates for Regiospecific Preparation of 2-[[(p-Nitrophenyl)sulfonyl]oxy] Ketones”, J. Org. Chem, 59(7): 1933-1936 (1994).
Aberhart, J., “(S)-(+)-2,3 Dihydroxy-3-methylbutanoic Acid by Syn Dihydroxylation of 3-Methylcrotonic Acid ”, J. Org. Chem, 45(25): 2518-5220 (1980).
Ramsey, B.G., et al., “Anisyl Neighboring Group Participation in Carbonium Ion Formation in Antimony Pentafluoride and Sulfur Dioxide”, J. Org. Chem, 37(21): 3310-3322 (1972).
Kita, Y., et al., “A Convenient Synthesis of Dicarboxylic Monoesters Using Isopropenyl Esters: Synthesis of Oxaunomycin Derivatives”, J. Chem Soc., Chem. Commun., 410-412 (1993).
Liesen, G., et a., “Activated Anhydrides of Tartaric and Malic Acid”, J. Organic Chemistry, 52(3):455-457 (1987).
Kurumbail, R.G. et al, Structural Basis for selective inhibition of cyclooxygenase2 by anti-inflammatory agents, Nature, 384(19/26): 644-648 (1996).
Li, J.J. et al, 1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents, J. Med. Chem., 38(22):4570-4578 (1995).
Li, J.J. et al, Novel Terphenyls as Selective Cyclooxygenase2 Inhibitors and Orally Active Anti-inflammatory Agents, J. Med. Chem., 39:1846-1856 (1996).
Magolds, R.L., Structure-Activity-Relationship (SAR) with a Novel Series of Selective Cyclooxygenase-2 Inhibitors, Dupont Merck Pharmaceutical Company, 1-4.
Mitchell, J.A., Cyclooxygenase-2: Regulation and Relevance in Inflammation, Biochemical Pharmacology, 50(10):53-60 (1995).
Nannini, G. et al, Synthesis and pharmacological activity of some 5, 6-diphenylpyridazines, Eur. J. Med. Chem., 14(1):53-60 (1979).
Tsuijii, M., et al., “Cyclooxygenase-2-in Human Colon Cancer Cells Increases Metastatic Potential”, Proc. Natl. Acad. Sci., 94: 3336-3340 (1997).
Penning, T.D. et al, Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-l-yl]benzenesulfonamide (SC-58635, Celecoxib), J. Med. Chem., 40:1347-1365 (1997).
Pinto, D.J.P. et al, Chemistry and Pharmacokinetics of Diarylthiophenes and Terphenyls as Selective Cox-2 Inhibitors1, Bioorganic & Medicinal Chemistry Letters, 6(24):2907-2912 (1996).
Reitz, D.B. et al., Novel 1,2-Diarylcyclopentenes are Selective, Potent, and Orally Active Cyclooxygenase Inhibitors, Med. Chem. Res., 5:351-363 (1995).
Reitz, D.B. et al., Selective Cyclooxygenase Inhibitors: Novel 4-Spiro 1,2- Diarylcyclopentenes are Potent and Orally Active COX-2 Inhibitors, Bioorganic & Medicinal Chemistry Letters, 5(8):867-872 (1995).
Bitan, G., et al., Building Units for N-Backbone Cyclic Peptides. 2. Synthesis of Protected N-(∞-thioalkylene)Amino Acids and Their Incorporation into Dipeptide Units, Tetrahedron, 1995, 51(38), 10513-10522.
Thérien, M., Synthesis and Biological Evaluation of 5,6-Diarylimidazo[2.1-b]Thiazole as Selective COX-2 Inhibitors, Bioorganic & Medicinal Chemistry Letters, 7(1):47-52 (1997).
Wilkerson, W.W. et al, Antiinflammatory 4,5-Diarylpyrooles. 2. Activity as a Function of Cyclooxygenase2 Inhibition, J. Med. Chem., 38:3895-3901 (1995).
Wilkerson, W.W. et al, Antiinflammatory 4,5-Diarylpyrooles: Synthesis and QSAR, J. Med. Chem., 37:988-998 (1995).
Wong, E et al, Conversion of Prostaglandin G/H Synthase—1 into an Enzyme Sensitive to PGHS-2-selective
Basha Anwer
Black Lawrence A.
Coghlan Michael J.
Kolasa Teodozyj
Kort Michael E.
Abbott Laboratories
Bernhardt Emily
Chen Portia
LandOfFree
Prostaglandin endoperoxide H synthase biosynthesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin endoperoxide H synthase biosynthesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin endoperoxide H synthase biosynthesis inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3672585